Glybera's additional benefits not quantifiable, says Germany
This article was originally published in Scrip
Executive Summary
The additional benefits of Chiesi/UniQure's orphan drug Glybera are not quantifiable, says the G-BA, the body in charge of Germany's AMNOG benefit assessments for new pharmaceuticals. The news comes after the G-BA last month slammed Chiesi for failing to properly disclose a potentially damming report from the European Medicines Agency.